Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.14

Margin Of Safety %

15

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.42

EPS Last/This Y

-0.31

EPS This/Next Y

Price

14.72

Target Price

16.81

Analyst Recom

1.88

Performance Q

11.09

Relative Volume

2.36

Beta

0.28

Ticker: TAK




23 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-05TAK15.040.200.052516
2025-03-06TAK14.990.190.062539
2025-03-07TAK15.180.190.012553
2025-03-10TAK15.030.180.022745
2025-03-11TAK14.90.180.072743
2025-03-12TAK14.940.180.002740
2025-03-13TAK15.030.180.042746
2025-03-14TAK15.010.180.002759
2025-03-17TAK15.170.170.072789
2025-03-18TAK15.180.170.172803
2025-03-19TAK15.120.170.012811
2025-03-20TAK15.150.170.632804
2025-03-21TAK15.190.210.212921
2025-03-24TAK15.020.190.282953
2025-03-25TAK15.060.200.042994
2025-03-26TAK15.010.200.523000
2025-03-27TAK15.140.200.063004
2025-03-28TAK15.060.201.333018
2025-03-31TAK14.870.210.002932
2025-04-01TAK14.90.200.002935
2025-04-02TAK14.970.200.002939
2025-04-03TAK15.190.200.002939
2025-04-04TAK14.720.170.903422
DateSymbolLastP/C OIP/C VolTotal OI
23 items Current Page1 of 1




23 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-05TAK15.04- 776.10.00
2025-03-06TAK15.01- 725.20.00
2025-03-07TAK15.17- 744.40.00
2025-03-10TAK15.04- 731.00.00
2025-03-11TAK14.90- 725.40.00
2025-03-12TAK14.94- 730.50.00
2025-03-13TAK15.03- 736.70.00
2025-03-14TAK15.01- 768.00.00
2025-03-17TAK15.18- 799.30.00
2025-03-18TAK15.18- 779.60.00
2025-03-19TAK15.13- 758.90.00
2025-03-20TAK15.16- 753.10.00
2025-03-21TAK15.20- 758.00.00
2025-03-24TAK15.01- 729.30.00
2025-03-25TAK15.04- 737.80.00
2025-03-26TAK15.02- 733.30.00
2025-03-27TAK15.14- 752.30.00
2025-03-28TAK15.05- 728.50.00
2025-03-31TAK14.87- 746.80.00
2025-04-01TAK14.90- 772.80.00
2025-04-02TAK14.98- 743.10.00
2025-04-03TAK15.19- 789.80.00
2025-04-04TAK14.72- 591.50.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
23 items Current Page1 of 1




23 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-05TAK0.00-0.970.13
2025-03-06TAK0.00-0.970.13
2025-03-07TAK0.00-0.970.13
2025-03-10TAK0.00-0.920.13
2025-03-11TAK0.00-0.920.13
2025-03-12TAK0.00-0.920.14
2025-03-13TAK0.00-0.920.14
2025-03-14TAK0.00-0.920.14
2025-03-17TAK0.00-0.890.14
2025-03-18TAK0.00-0.890.14
2025-03-19TAK0.00-0.890.14
2025-03-20TAK0.00-0.890.14
2025-03-21TAK0.00-0.890.14
2025-03-24TAK0.00-0.840.14
2025-03-25TAK0.00-0.840.14
2025-03-26TAK0.00-0.840.14
2025-03-27TAK0.00-0.840.14
2025-03-28TAK0.00-0.840.14
2025-03-31TAK0-0.880.14
2025-04-01TAK0-0.880.14
2025-04-02TAK0.00-0.880.14
2025-04-03TAK0.00-0.880.14
2025-04-04TAK0.00-0.880.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
23 items Current Page1 of 1

Last Quarter Act. EPS

0.42

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-0.88

Beta

0.28

Average Sales Estimate Current Quarter

1077450

Average Sales Estimate Next Quarter

1151000

Fair Value

16.87

Quality Score

69

Growth Score

73

Sentiment Score

93

Actual DrawDown %

26.4

Max Drawdown 5-Year %

-31.4

Target Price

16.81

P/E

34.62

Forward P/E

28.59

PEG

1.24

P/S

1.54

P/B

0.99

P/Free Cash Flow

8.25

EPS

0.43

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.51

Relative Volume

2.36

Return on Equity vs Sector %

-17

Return on Equity vs Industry %

-5.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

591.5
Takeda Pharmaceutical Company L
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 49281
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
stock quote shares TAK – Takeda Pharmaceutical Company Limited Stock Price stock today
news today TAK – Takeda Pharmaceutical Company Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TAK – Takeda Pharmaceutical Company Limited yahoo finance google finance
stock history TAK – Takeda Pharmaceutical Company Limited invest stock market
stock prices TAK premarket after hours
ticker TAK fair value insiders trading